12/1
06:59 pm
atxs
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
12/1
03:20 pm
atxs
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
11/30
01:32 am
atxs
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold [Seeking Alpha]
Low
Report
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold [Seeking Alpha]
11/18
07:20 am
atxs
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
11/12
06:11 pm
atxs
Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition [Yahoo! Finance]
Low
Report
Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition [Yahoo! Finance]
11/12
01:55 pm
atxs
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
11/12
12:58 pm
atxs
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
Neutral
Report
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
11/12
08:23 am
atxs
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/12
08:00 am
atxs
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Low
Report
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/6
08:00 am
atxs
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Low
Report
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
10/31
08:00 am
atxs
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Low
Report
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
10/24
12:16 pm
atxs
Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
01:50 pm
atxs
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
Low
Report
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
10/17
03:20 pm
atxs
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Low
Report
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
10/16
08:08 am
atxs
Astria Therapeutics (NASDAQ:ATXS) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
10/15
08:12 am
atxs
Astria Therapeutics (NASDAQ:ATXS) had its "market perform" rating reaffirmed by analysts at JMP Securities.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) had its "market perform" rating reaffirmed by analysts at JMP Securities.
10/15
08:03 am
atxs
Astria Therapeutics (NASDAQ:ATXS) was given a new $13.00 price target on by analysts at Wedbush.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) was given a new $13.00 price target on by analysts at Wedbush.
10/14
09:05 pm
atxs
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
10/14
06:09 pm
atxs
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
10/14
02:20 pm
atxs
Astria Therapeutics (NASDAQ:ATXS) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $13.00 price target on the stock, down previously from $30.00.
Low
Report
Astria Therapeutics (NASDAQ:ATXS) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $13.00 price target on the stock, down previously from $30.00.
10/14
12:00 pm
atxs
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders
Low
Report
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders
10/14
11:25 am
atxs
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
10/14
08:29 am
atxs
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
Medium
Report
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
10/14
07:00 am
atxs
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
High
Report
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
10/11
03:05 pm
atxs
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed [Yahoo! Finance]
Low
Report
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed [Yahoo! Finance]